Clinical Trials Logo

Clinical Trial Summary

A Phase 2 study to evaluate safety and efficacy of sildenafil taken orally to improve or resolve lymphatic malformations in children. Subjects may receive either placebo or treatment in an oral dosage with an open label extension for subjects who received placebo. The study treatment assignment will be randomized in a double blind fashion. MRI examination will evaluate change in lesion volume due to treatment. Other safety and efficacy measures will be taken through the 32-week study duration. Funding Source - FDA OOPD


Clinical Trial Description

Lymphatic malformations (LMs) are localized areas of abnormal development of the lymphatic system that commonly occur in the head and neck of children. LMs are considered a rare or orphan disease which causes complications including pain, ulceration, secondary infection, infiltration of other organs, and death. Current therapies involve surgical excision or methods of chemical or physical destruction of portions of lesions. No therapies are uniformly effective and all have the risk of significant adverse events. We recently witnessed almost complete resolution of a LM lesion in a child who was treated with sildenafil oral therapy for pulmonary arterial hypertension. We have subsequently evaluated additional subjects who improved with sildenafil. The goal of this clinical research trial is to document the benefit or absence of benefit of sildenafil therapy for LMs and identify which type of patient will benefit from sildenafil. This study is a double-blind placebo-controlled trial which involves precise documentation of volume changes associated with therapy or placebo by using MRI segmentation techniques. We will also observe and document the clinical response to sildenafil or placebo using clinical evaluation scores and surveys. The results of the study should identify characteristics of LM lesions which may suggest a beneficial response to sildenafil therapy. Sildenafil has very low risk of side effects in the dosage used in this trial. Documentation of an effective response of LMs to sildenafil will accelerate the interest in, and the ability to understand, the mechanisms of LM formation and treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02335242
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase Phase 2
Start date May 23, 2015
Completion date March 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT02497131 - Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients Phase 2
Recruiting NCT01451502 - Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units N/A
Active, not recruiting NCT03264131 - BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma Phase 2
Completed NCT03744676 - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Phase 2
Completed NCT03135535 - Micro-mobile Foot Compression and Diabetic Foot Phase 2
Active, not recruiting NCT05441943 - Lymphaticovenous Anastomosis as Treatment for Lymphedema N/A
Recruiting NCT06267807 - Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders N/A
Withdrawn NCT05431179 - A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Phase 3
Recruiting NCT05731141 - A Prospective Natural History Study of Lymphatic Anomalies
Recruiting NCT03696784 - Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Phase 1
Completed NCT03709407 - "Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study" N/A
Active, not recruiting NCT02663297 - Administration of T Lymphocytes for Prevention of Relapse of Lymphomas Phase 1
Completed NCT05683444 - Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial Early Phase 1
Completed NCT02960841 - Effectiveness of Intracavitary Manual Lymphatic Drainage Phase 4
Recruiting NCT05263583 - Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma Phase 2
Terminated NCT02499627 - Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting Phase 2
Recruiting NCT03373019 - Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Phase 2
Recruiting NCT03602157 - Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Phase 1
Recruiting NCT02690545 - Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Phase 1/Phase 2
Completed NCT02744027 - Imaging of Lymphatic Anomalies N/A